D. P

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Retrieved on: 
Thursday, March 16, 2023
Anatomy, Surgeon, United Kingdom, Timmer, BRAVO, Risk, Infection, Case series, Hernia, Patient, S. Sivaraj, Capillary action through synthetic mesh, Biosynthesis, Consultant, Cohort (statistics), Publication, D. P, DOI, Use, Recurrence, Medical imaging, Dentistry, Victor Trotsyuk, Claessen

(NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.
  • It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom.
  • Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization.
  • * Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study.